Ongoing Projects

European flagAROMICS has a clear international vision. From its inception, the company has participated in the establishment of a biotechnology strategy in Europe to improve commercial and production activities of small and medium size companies.

AROMICS has proven experience in R&D Projects under various funding programs: European (Horizon 2020), national (CDTI) and local (ACC1Ó-FEDER). The active participation of the company in European funded R&D projects as well as membership in different European platforms enables the company to:

  • Be at the forefront of European research.
  • Identify, improve and implant new technologies with potential applications in the health sector(industry and clinical practice).
  • Favor technology transfer.
  • Share the costs of innovation through partnerships with other biotechnology and pharmaceutical companies.

The aim of the project is to develop a novel treatment for Malignant Mesothelioma, a rare, aggresive and poorly responsive cancer directly related to asbestos exposure. General objective pursued by the project include to complete non-regulatory preclinical studies and conduct a clinical trial in patients.

(Co-financed by the Horizon 2020 Programme of the European Union)

(Co-financed by CDTI through the Horizon Europe EIC Accelerator Seal of Excellence SME Programme)

METACAN aims to gaining understanding on how modulating cell metabolism may interfere with tumor growth focusing  as well in terms of the interactions between cancer and immune cells. The knowledge acquired will serve as a platform for drug discovery and diagnostics efforts that aim to therapeutically target metabolism, inflammation or immune responses for the treatment of a variety of cancers.

(Co-financed by the Horizon 2020 Programme of the European Union)

AMMIC project focuses on the implementation of a drug discovery and development platform, from early stages up to clinical trials, to accelerate the discovery of medicines for rare disease (the so called orphan drugs). Other aspects like genomics, epigenomics, transcriptomics and liquid biopsies are also addressed inside the project, in order to improve as well the diagnosis and managment of rare diseases, with a particular focus on pediatric oncology conditions.

(Co-financed by FEDER  programme)